ABBVAbbVieRunning, no new patients
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Blastic Plasmacytoid Dendritic Cell Neoplasm · Myeloproliferative Neoplasm
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 179 (final count)
- Started
- Jan 2, 2018
- Main results expected
- Oct 2, 2024
- Fully finished
- Dec 30, 2026
- Results posted
- Sep 4, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants
Measured over: Up to approximately 81 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03386513 · record last updated 2026-09-04 · checked 2026-11-09 15:47 UTC